» Articles » PMID: 35043090

Enhanced Endocytosis Elevated Virulence and Severity of SARS-CoV-2 Due to Hyperglycemia in Type 2 Diabetic Patients

Overview
Journal Gene Rep
Date 2022 Jan 19
PMID 35043090
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus is a metabolic disease that causes hyperglycemia. In COVID-19 patients the severity of the disease depends on myriad factors but diabetes mellitus is the most important comorbidity. The current review was conducted to investigate the virulence of SARS-CoV-2 and disease severity of COVID-19 in type 2 diabetes mellitus patients and relevant treatment. The literature published in PubMed, Scopus, Web of Science, and Google Scholar was reviewed up to September 2021. The keywords including SARS-CoV-2, type 2 diabetes mellitus in COVID-19, hyperglycemia in COVID-19, opportunistic infections in type 2 diabetes mellitus and COVID-19 were used in different combinations. Hyperglycemic individuals over-express ACE-2 receptors in the lungs thus increasing the SARS-CoV-2 susceptibility and replication. Although dipeptidyl peptidase-4 plays an important role in glucose homeostasis, additionally it also stimulates the production of proinflammatory cytokines such as IL-6 and TNF-α creating a cytokine storm. Cytokine storm might be responsible for respiratory insufficiency in severe COVID-19 patients. Type 2 diabetes mellitus is associated with immunosuppression and the patients are prone to get many opportunistic infections. Type 2 diabetes mellitus patients with severe COVID-19 have lymphopenia. Moreover, in type 2 diabetes mellitus patients the neutrophils exhibit decreased chemotaxis, hydrogen peroxide production, and phagocytosis. Reduction in lymphocyte count and defective neutrophil capacity renders them with COVID-19 susceptible to opportunistic bacterial and fungal infections increasing the mortality rate. The opportunistic bacterial infections in COVID-19 patients were due to , pneumonia, and coagulase-negative Staphylococci, . , , and sp. In COVID-19 patients with type 2 diabetes mellitus, mucormycosis was found to be the most common fungal infection with a higher predilection to males. Hyperglycemia in COVID-19 patients with type 2 diabetes mellitus enhances the SARS-CoV-2 replication with an adverse outcome. A strong correlation exists between the poor prognosis of COVID-19 and type 2 diabetes mellitus. Proper glycemic control in COVID-19 patients with diabetes mellitus might lessen the severity of the disease.

Citing Articles

Impacts of Inflammatory Cytokines Variants on Systemic Inflammatory Profile and COVID-19 Severity.

Deng X, Tang K, Wang Z, He S, Luo Z J Epidemiol Glob Health. 2024; 14(2):363-378.

PMID: 38376765 PMC: 11176143. DOI: 10.1007/s44197-024-00204-w.


What's old is new again: Insights into diabetic foot microbiome.

Rajab A, Hegazy W World J Diabetes. 2023; 14(6):680-704.

PMID: 37383589 PMC: 10294069. DOI: 10.4239/wjd.v14.i6.680.


Diabetes mellitus: Lessons from COVID-19 for monkeypox infection.

Ruiz-Pacheco J, Castillo-Diaz L, Arreola-Torres R, Fonseca-Coronado S, Gomez-Navarro B Prim Care Diabetes. 2023; 17(2):113-118.

PMID: 36737358 PMC: 9884624. DOI: 10.1016/j.pcd.2023.01.008.

References
1.
Jin S, Hu W . Severity of COVID-19 and Treatment Strategy for Patient With Diabetes. Front Endocrinol (Lausanne). 2021; 12:602735. PMC: 8121170. DOI: 10.3389/fendo.2021.602735. View

2.
Chen S, Zhu Q, Xiao Y, Wu C, Jiang Z, Liu L . Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: An observational study. Clin Respir J. 2021; 15(7):815-825. PMC: 8250518. DOI: 10.1111/crj.13369. View

3.
Peng M, Meng H, Sun Y, Xiao Y, Zhang H, Lv K . Clinical features of pulmonary mucormycosis in patients with different immune status. J Thorac Dis. 2020; 11(12):5042-5052. PMC: 6988080. DOI: 10.21037/jtd.2019.12.53. View

4.
Rajpal A, Rahimi L, Ismail-Beigi F . Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes. 2020; 12(12):895-908. PMC: 7405270. DOI: 10.1111/1753-0407.13085. View

5.
Haythorne E, Rohm M, van de Bunt M, Brereton M, Tarasov A, Blacker T . Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells. Nat Commun. 2019; 10(1):2474. PMC: 6554411. DOI: 10.1038/s41467-019-10189-x. View